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Abstract
TCAP encoded telethonin is a 19 kDa protein, which plays an important role in anchoring titin in Z disc of the sarcomere,
and is known to cause LGMD2G, a rare muscle disorder characterised by proximal and distal lower limb weakness, calf
hypertrophy and loss of ambulation. A total of 300 individuals with ARLGMD were recruited for this study. Among these we
identified 8 clinically well characterised LGMD2G cases from 7 unrelated Dravidian families. Clinical examination revealed
predominantly proximo - distal form of weakness, scapular winging, muscle atrophy, calf hypertrophy and foot drop,
immunoblot showed either complete absence or severe reduction of telethonin. Genetic analysis revealed a novel nonsense
homozygous mutation c.32C.A, p.(Ser11*) in three patients of a consanguineous family and an 8 bp homozygous
duplication c.26_33dupAGGTGTCG, p.(Arg12fs31*) in another patient. Both mutations possibly lead to truncated protein or
nonsense mediated decay. We could not find any functionally significant TCAP mutation in the remaining 6 samples, except
for two other polymorphisms, c.453A.C, p.( = ) and c.-178G.T, which were found in cases and controls. This is the first
report from India to demonstrate TCAP association with LGMD2G.
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Introduction
The seventh form of Autosomal Recessive Limb-Girdle
Muscular Dystrophy (LGMD2G; OMIM 601954) is caused by
genetic variations in the telethonin gene (also named as TCAP or
titin-cap gene) (NM_003673.3). LGMD2G has been mapped to
chromosome 17q12 [1]. LGMD2G was first described from Brazil
[2]; subsequently it was reported from China [3], Moldavia [4],
and Portugal [5]. Onset of this disease is usually in the second
decade, with predominant pelvic girdle weakness and associated
distal weakness with foot drop [2]. About50% of the cases are
known to have calf hypertrophy and 40% are known to lose
independent ambulation during the third or fourth decade [1].
Telethonin is amongst the most abundant nuclear mRNA
transcribed in skeletal muscle and encodes for a 19 kDa protein
consisting of 167 amino acids [6]. The protein is located in the
Z-disc of sacromere, the basic functional contractile unit in the
skeletal and cardiac muscles [6,7,8]. Telethonin plays an
important role in the sarcomeric assembly as it joins the two
antiparallel titin (Z1-Z2) domains together through beta strand
crossing and represents the strongest protein–protein interaction
observed so far [9,10,11,12]. Telethonin is also known for its
interaction with other Z-disc proteins of sarcomeric assembly such
as LIM protein (MLP) [13], Ankrd2 [14], myostatin [15],
potassium channel B-subunit minK [16], protein kinase D [17],
murine double minute2 (MDM2) [18],and calsarcin [19]. Thus,
TCAP is expected to play a very important role in the sarcomeric
assembly.
It has been demonstrated that the TCAP knockout mouse
resulted in a modest increase in passive muscle stiffness and shared
many of the features of LGMD 2G phenotype [20]. Looking at the
functional importance of telethonin in muscles, we have analysed
TCAP in eight patients of Dravidian origin (south-India) in order
to identify TCAP mutations in LGMD2G.
Materials and Methods
Subjects
This study was approved by the Institutional Ethical Committee
(IEC) of Centre for Cellular and Molecular Biology, Hyderabad,
India and National Institute of Mental Health and Neurosciences,
Bangalore, India. The subject recruitment and sample collection
were done after obtaining written informed consent/assent forms
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from all participants. In this prospective study (February 2010 to
September 2012) a total of 300 patients with features of
ARLGMD were prospectively evaluated by the principal investi-
gator (AN) at the National Institute of Mental Health and
Neurosciences. Of these 300 cases, 246 patients were confirmed to
have various forms of ARLGMD based on characteristic clinical
phenotype, biochemical and histopathological analysis. IB was
performed sequentially based on the IHC results to confirm the
type of ARLGMD.
Sequence analysis of TCAP gene was undertaken in the eight
cases which were found to be LGMD2G based on immunoblot-
ting. All patients hailed from South India and shared the ethnic
origin (Dravidian linguistic group). Family members, wherever
available, were included in the analysis. Among these 7 families,
one (F50) had two more affected siblings. Family (F111) also had
one affected sibling (F111-2), who was available for clinical
examination and genetic analysis, but muscle biopsy was not done.
In total, we have studied 8 patients and 49 related family
members. The inclusion criteria for the index cases were: clinical
phenotype consistent with LGMD2G, elevated creatine kinase
(CK) level, and loss or severe reduction of telethonin expression in
IB studies. One hundred and sixty seven control samples, after
ruling out muscular dystrophy or family history of muscular
dystrophy, were recruited for comparison purpose.
Histopathology and Immunohistochemistry (IHC)
Muscle biopsy. Open biopsy from the quadriceps femoris or
biceps brachii muscle was performed in 280 patients. Samples
were flash frozen in isopentane chilled in liquid nitrogen. Serial
Table 1. Primer sequence used for the TCAP amplification.
Name Forward Reverse Annealing temp
TCAP 1F TTCTGCTTCCCACTTTATGAAAA AGAAGGGAGAGTGCAACCAC 55
TCAP 2F GTGAGGGTGACTGGGGACTA GAAATTTCTCCAGGGCTTCA 54
TCAP 3F GAGAGCAAAGGGGAACCAC ACCCTCCCTTTGGGAACTC 55
TCAP 4F GCCATGGCTGCTTTGTAGT TGGGGTGTACCCATTAGCTC 54
doi:10.1371/journal.pone.0102763.t001
Figure 1. Transversely cut skeletal muscle tissue stained for Haematoxylin and eosin (HE) shows variation in fiber diameter clusters
of basophilic regenerating fibers and myophagocytosis. Immunolabeling to antibodies against dystrophin (dys1,dys2,dys3) sarcoglycans
(alpha-A, beta-B, delta-D, gamma-G, merosin, dysferlin (DYSF), caveolin, beta dystroglycan (B-DG), alpha dystroglycan (A-DG) shows uniform labeling
along the sarcolemma and positive sarcoplasmic labeling to titin. X400
doi:10.1371/journal.pone.0102763.g001
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frozen sections were stained with hematoxylin and eosin (HE),
modified gomoritrichome (MGT), succinic dehydrogenase (SDH),
nicotinamide adenine dinucleotide (NADH-TR), succinic dehy-
drogenase–cytochrome C oxidase (SDH-COX), and adenosine
triphosphatase (ATPase pH 9.4,4.6).
Antibodies. IHC staining was carried out on fresh frozen
sections using monoclonal antibodies against dystrophin (1,2,3),
sarcoglycans (a,b,d,c), dysferlin, caveolin-3, titin, merosin (a2
laminin) (Novocastra Laboratories, Newcastle, UK) and a-
dystroglycan (Santacruz Biotechnology, Santacruz, CA, USA) as
primary and HRP tagged NOVO linked as secondary antibody
(Novocastra Laboratories, Newcastle, UK).
Preparation of protein extracts, SDS-PAGE and
immunoblot
Frozen muscle tissue (20 mg) was minced in 20 volumes of
extraction buffer (75 mM Tris-HCl, pH 6.8, 15% SDS, 20%
glycerol, 5% dithiothreitol and 0.001% bromophenol blue),
homogenized and sonicated for 30 seconds (6 x 5s).The extract
was boiled at 95uC for 5 minutesfollowed by centrifugation at
12000 rpm for 10 minutes. 10 ml of the supernatant was subjected
to size fractionation using 15% SDS-PAGE followed by western
blot using anti-Telethonin antibody (monoclonal antibody G-11,
Santacruz Biotech) [21]. For myosin profile (loading control),
protein extracts were run on 6% SDS-PAGE and stained with
coomassie brilliant blue. To avoid artifactual protein degradation,
which might reduce telethonin signal, precaution was taken to
preserve the integrity of the biopsies and to maintain optimal
protein loading and gel transfer conditions.
Muscle MR Imaging
Muscle MRI was performed as a multi-sequence imaging
protocol using a 1.5-T scanner (Magnetom, AERA, Siemens).
Sections were obtained from axial planes including a T1-weighted
spin-echo sequence (repetition time –918 msec, echo time
9.7 msec) and a short-time inversion recovery (STIR) sequence
(repetition time 4020 msec, echo time 99 msec, inversion time
150 msec), in 10-mm slices. Involvement of all thigh and lower leg
muscles was staged according to the intensity of the increased
signals depicting fatty infiltration and STIR sequences for
myoedema. Images were analyzed for signs of muscle degenera-
tion, edema and normal/abnormal muscle bulk (hypertrophy,
atrophy). Muscles evaluated on MRI: At pelvis: gluteus maximus,
medius, minimus, piriformis, iliopsoas; Thighs: vastusmedialis,
intermedius and lateralis, gracilis, sartorius, adductor muscles,
tensor fasciae latae, rectus femoris, semimembranosus, semitendi-
nosus, biceps femoris; Lower legs: tibialis anterior, extensor
hallucis longus, peroneii, soleus, popliteus, extensor digitorum
longus, medial and lateral head of gastrocnemius, tibialis posterior.
The fibro-fatty replacement was evaluated on T1sequences by
applying Mercuri score [22]; and myoedema was evaluated on
STIR sequences by using a specific new oedema score [23].
Genetic analysis of TCAP
About 5.0 ml of peripheral blood sample from each participant
was collected in EDTA vacutainers. DNA was isolated according
to the protocol described in our earlier study [24]. The coding
region, including exon-intron boundaries and the UTR regions of
Telethonin gene were amplified using 4 sets of primers. The
sequence of primers and the conditions used for amplification are
given in Table 1. PCR was performed in 0.2 ml thin-walled tubes
using 50.0 ng of genomic DNA, 10 pmol of each primer, 200 mM
of dNTPs, PCR buffer containing 1.5 mM MgCl2, and 2 units of
AmpliTaqGold (Perkin Elmer). Amplified products were evaluated
using 2% agarose gel electrophoresis. PCR products were purified
by treating with exonuclease I and Shrimp alkaline phosphatase
(Amersham, Piscataway, NJ) at 37uC and 80uC for 15 minutes
each. Sequencing of PCR products was carried out using 100.0 ng
(2.0 ml) of PCR product and 4 pmol (1.0 ml) of primer (forward
and reverse in separate reactions), and 4.0 ml of BigDye
Terminator ready mixture (Applied Biosystem, Foster city,
USA). Cycle sequencing was carried out in a GeneAmp 9600
thermal cycler (Applied Biosystem, Foster city, USA) employing
the following conditions: 30 cycles at 96uC for 10 seconds, 50uC
for 5 seconds, and 60uC for 4 minutes. PCR amplicons were
purified using the protocol described in our earlier study [25],
dissolved in 10 ml of 50% Hi-Di formamide and analyzed using
ABI 3700 automated DNA analyzer (Perkin Elmer). The
sequences obtained were aligned with NCBI Reference Sequence:
NG_008892.1 (gene)/NM_003673.3 (mRNA) using the Auto-
Assembler software to identify the sequence variations.
Results
Clinical features
Based on the combined IHC and IB results, the commonest
form of ARLGMD was LGMD 2B (Dysferlin) in 82/246
(33.33%); followed by 2I (FKRP) in 51/246 (20.73%), 2C-F
(gamma, alpha, beta and delta sarcoglycan) in 35/246 (14.23%),
2A (calpain-3) in 25/246 (10.16%), and 2G (Telethonin) in 8/246
(3.25%). The remaining cases (45/246-18.30%) remained unclas-
sified.
The age of onset of LGMD2G cases ranged from 5 to 40 years
(mean 6SD, 12.38611.35) and the mean age at evaluation and
mean duration of illness were 22.8614.2, (9–52 years) and
Figure 2. Western blot analysis of telethonin protein in muscle
biopsies of control and telethoninopathy patients. A. Telethonin
western Blot: Lane C corresponds to non-dystrophic positive control
which shows telethonin band at 19 kDa. Lanes 1–7 corresponding to
the Telethoninopathy patient samples, shows complete absence of the
telethonin band. B. Coomassie stained SDS PAGE (15%) profile of total
muscle extract from the samples.
doi:10.1371/journal.pone.0102763.g002
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8.5066.87 (2–23 years), respectively. Gender distribution was
equal. CK value ranged from 718 to 9253 IU/L (mean 6 SD,
2574.462847.52). The clinical features and histopathological
findings of the patients are presented in Table 2. IB studies in 7
patients (Biopsy not done for F111-2) showed normal expression of
dystrophin, dysferlin, calpain-3 and all four sarcoglycans with
complete or partial absence of telethonin on IB (Fig 1-2). A
majority of patients had the typical phenotype with predominantly
a proximo - distal form of involvement, scapular winging, muscle
atrophy, presence of calf hypertrophy and foot drop and slowly
progressive in most cases.
Muscle MRI findings
MRI findings of the patient, 97-1 (Fig 3), revealed: At Pelvis:
gluteus maximus showed stage 2b fatty infiltration and iliopsoas
showed stage 2a involvement. Rectus femorus was atrophied; At
thighs: global atrophy of muscles of all three compartments.
Sartorius, gracilis, semitendinosus and short head of biceps were
spared and also hypertrophied. In the anterior compartment
vastus, intermedius showed severe atrophy. Myoedema was mainly
seen in the anterior compartment and more on the left side. In the
posterior compartment, stage 2b myoedema was seen only on the
left side; At legs: Atrophy of tibialis anterior, extensor digitorum
longus, extensor hallucis longus, flexor hallucis longus, flexor
digitorum longus was noted. Medial head of gastrocnemius was
hypertrophied. Soleus appeared to be atrophied on left side and
preserved on right side. Myoedema was noted only in gastrocne-
mius and soleus muscles. MRI staging of the affected individual
muscles are listed in table 3.
Sequence analysis
The TCAP gene was analysed in ten patients (including two
affected siblings from family F50), belonging to seven unrelated
families. We have identified four different mutations that included;
one novel and three reported variations (www.dmd.nl). Mutation
numbering was based on TCAP cDNA with sequence position 1
being the A in the first ATG codon. The novel mutation (c.32C.
A) (Fig 4C) is a nonsense substitution in the first exon, which
introduces a stop codon (TCG to TAG) in three patients
(homozygous mutant) of a consanguineous family (F50) (Table 4).
All the unaffected family members were either heterozygous or
homozygous for the alternate allele (Fig 4A). None of the control
samples had this mutation.
The second variation is an eight base pair duplication in the
first exon (c.26_33dupAGGTGTCG), (Fig 4F) which leads to an
amino acid change from 12th codon and terminates at
31stcodon, resulting in the formation of a truncated protein in
one of the patients (F97-1) (Table 4). Both the parents, two
brothers, and the grandfather were found to be heterozygous for
this duplication and were unaffected (Fig 4B). This mutation was
not found in the control samples. Two other mutations; c.453A.
C; p.(= ) in exon2and c.-178G.T of the 59 UTR region; were
polymorphic and found in all the patients, their relatives, and
control samples.
Discussion
For the first time in India, we have performed a comprehensive
analysis of LGMD2G, a rare muscle disease caused by telethonin
protein deficiency encoded by the TCAP gene. The clinical
manifestations in all our patients was classical, with a phenotype
consisting of mild to moderate limb girdle muscle weakness,
significant thigh and anterior leg atrophy with weakness, mildT
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scapular winging and calf hypertrophy. The mutational analysis
revealed one novel and three reported substitutions.
The c.32C.A, p.(Ser11*) mutation is a novel, nonsense change
and exists in the N-terminal region of the gene. Serine in the
codon 11 was replaced by premature translational termination
codon and it may lead to nonsense mediated decay or truncated
protein. This mutation was found in a patient born to
consanguineous parents (F50-1). The proband was a 10 year old
boy and was the ninth child born to a first cousins marriage. He
presented with exertion induced calf muscle pains and progressive
toe walking from eight years of age, progressive pectoral girdle,
arm and lower limb proximal muscle wasting with weakness,
scapular winging and mild foot drop. There was significant global
wasting of the thigh and anterior leg muscles with hypertrophied
calves and tip toe walking. Biceps muscle biopsy revealed a
dystrophic changes. He had two sisters (F50-8 and F50-9) with
similar phenotype, both of who had this mutation in the
homozygous condition (Fig 4A). The case F50-8, aged 25 years,
attained wheelchair bound state at 21 years of age and the case
F50-9 is ambulant at 17 years of age. All three affected individuals
of a family had the same mutation, were affected by eight years of
age and showed similar phenotype. The father, one sister, one
brother, one paternal uncle, and a maternal aunt were heterozy-
gous for this mutation and were unaffected. The other unaffected
brother, sister, and maternal uncle did not have the mutation
(Fig 4A). This clearly shows the recessive pattern of the disease and
pathogenicity associated with the mutation c.32C.A.
Frame shift variation c.26_33dupAGGTGTCG, (eight base
pair duplication) in the first exon observed in a 21 year old
proband (Fig 5) leads to an amino acid change from 12th codon
and terminates the reaction at 31st codon, p.(Arg12fs31*). This
may result in a truncated protein or nonsense mediated decay.
The c.26_33dupAGGTGTCG has been reported in three
unrelated Chinese families [26] and ours is the fourth family
from Asia, but the first from India. This mutation is consistent with
previous reports [3,26] confirming that homozygous individuals
have the typical LGMD2G phenotype. This patient (F97-1)
presented with motor disabilities since early childhood with
inability to run fast. By the age of 10 he had progressive
generalized wasting and lower limb proximal muscle weakness. He
was slender built, had moderate scapular winging, mild calf
hypertrophy and contractures at the hips and ankles (Fig 5). There
Figure 3. Muscle MRI of patient F97-1. A. T1W image showing
global atrophy of muscles of anterior compartment, medial compart-
ment and posterior compartment of thigh. Biceps femoris long head
shows stage 3 fatty infiltration. Short head of biceps femoris, sartorius
and gracilis are hypertrophied; B. shows severely atrophied vastus
intermedius muscle, Mercurie stage 2b infiltration of vastus medialis
muscle. Short head of biceps femoris, sartorius and gracilis are
hypertrophied; C. Tibilialis anterior, extensor hallucis longus and
extensor digitorum longus are atrophied (right more than left). On
right side the medial head of gastrocnemius is hypertrophied and
lateral head is atrophied. Left soleus is atrophied. Mild fatty infiltration
of soleus muscle is noted in left side. Striking asymmetry is present; D.
STIR image of thigh shows asymmetrical myoedema pattern. On the
right side there is stage 3a myoedema and on the left side it is stage 2a.
There is stage 2b myodema noted in the posterior compartment on left
side; E. Myoedema mainly seen in gastrocnemius and soleus muscle.
Stage 2b on right side and stage 2a on left side.
doi:10.1371/journal.pone.0102763.g003
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was MRC grade 4- weakness of the gluteus maximus, iliopsoas,
quadriceps and hamstrings with mild asymmetry. Foot dorsiflexors
were grade 3+ and other groups had normal power with elevated
CK level and normal ECG and 2D ECHO. EMG was myopathic,
nerve conductions were normal, pulmonary function tests showed
moderate restrictive abnormality, and biceps muscle biopsy
revealed dystrophic features. Parents, two brothers, and the
grandfather were found to be heterozygous and unaffected.
Both, c.32C.A and c.26_33dupAGGTGTCG, mutations lead
to truncation of the telethonin protein. Interestingly, all of the
mutations reported (p.Gln35*, g.637–640del2, p.Trp25*,
c.26_33dupAGGTGTCG), so far, in the TCAP gene in
LGMD2G have been either nonsense or frame shift variation,
which either gives rise to a truncated protein or terminates protein
synthesis [2,4,27,28]. To this list, we are adding a novel nonsense
mutation.
Out of the eight patients studied, few had significant degree of
toe walking from the onset of illness and this feature has been
described earlier. [4]. In the previous reports, the onset of illness
ranged between 2–15 years of age, with muscle weakness in all
limbs, calf hypertrophy, and marked weakness of distal anterior leg
muscles [29,30]. Our patients also had similar age of onset and a
comparable pattern of muscle involvement. Even though it is
reported that TCAP is necessary for the cardiomyocyte’s stretch
sensor and the structural organization of the cardiac sarcomere
[31,32,33], none of our cases had evidence of clinical or
echocardiographic evidence of cardiac dysfunction at the time of
clinical evaluation. Muscle biopsy has been reported to show
dystrophic features with or without rimmed vacuoles [4,27]. In our
study, rimmed vacuoles were not noted in any case.
Certain muscle MRI findings observed in one of our proband’s
(case- 97-1) were comparable to those reported in a previous
report [5]. Clinical examination revealed marked global atrophy
of thigh muscles and atrophy of muscles in the anterior
compartment of the leg. MRI showed a comparable pattern with
atrophy of muscles in all three compartments of the thigh and
anterior leg muscles. Sartorius, gracilis, semitendinosus, short head
of biceps and medial head of gastrocnemius were spared and also
hypertrophied. Anterior tibialis, extensor hallucis longus and
extensor digitorum longus muscles showed prominent atrophy.
The gastrocnemius muscles were slightly atrophic. Symmetry was
noted in all the features. Only one previous report on a 50 year old
Portuguese patient, describes the MRI findings of the muscles of
the thighs and legs [5]. Myoedema was observed in anterior thigh
and posterior leg muscles, which were relatively less affected.
These features are unique and have not been reported so far. The
Portuguese patient had demonstrated a homozygous nonsense
c.157C.T (p.Gln53*) mutation in exon 2 of the TCAP gene, as
Figure 4. Mutational analysis of TCAP gene. A&B. Pedigree of F50 & F97 families respectively and the arrow indicates the proband; C.
Electrophorogram representing heterozygous, homozygous and wild type c.32C.A mutation from family F50; Arrow indicates the polymorphic site;
D. IB representing absence of telethonin band in F50-1 and F97-1; (E). Represents myosin bands of F50-1 and F97-1; (F). Electrophorogram
representing homozygous, heterozygous and wild type c.26_33dupAGGTGTCG mutation in family F97.
doi:10.1371/journal.pone.0102763.g004
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described among Brazilian patients [1]. We have identified a 8 bp
duplication c.26_33dupAGGTGTCG, which is reported among
Chinese patients [26].Although LGMD2G may have phenotypic
characteristics ofLGMD-2A, 2B, the sarcoglycanopathies and
distal myopathies with rimmed vacuoles (DMRV), it could be well
differentiated from these disorders noting that LGMD-2A usually
does not have thigh atrophy or rimmed vacuoles. LGMD-2B has
predominantly posterior leg muscle weakness with calf muscle
wasting, sarcoglycanopathies do not have foot drop or rimmed
vacuoles, DMRV have progressive anterior leg muscle wasting and
weakness with sparing of quadriceps. In comparison, in LGMD2G
there is presence of significant atrophy of the thigh muscles
including quadriceps and significant involvement of anterior
tibialis. The predominant involvement of pelvic girdle muscles
with calf hypertrophy observed in LGMD2G resembles the
phenotype of some LGMD-2I. However, in 2G patients the thigh
muscles are severely affected along with tibialis anterior weakness
and wasting [29,30]. Thus, patients in the present series had the
typical phenotypes described in LGMD2G and the genetic
analysis confirms the same in two cases.
It has been reported that at least 25% of families and 40% of the
isolated cases have no detectable mutation in any of the reported
LGMD genes [34]. In agreement to this, we did not find any
genetic variation in the telethonin gene in the remaining six IB
confirmed cases. However, all of them showed partial or complete
absence of telethonin on IB. This may be due to the secondary
reduction of TCAP protein by some other Z-disk gene and
probably involves a combination of genetic factors, since no
protein in the Z-disc can be considered as an island separated from
the others [35]. Many human diseases however, can be expected
to be genetically heterogeneous caused by any one of several
genes. The autosomal recessive limb-girdle muscular dystrophies
represent a heterogeneous group of diseases which may be
characterised by one or more autosomal loci. Further investiga-
tions may help in identification of additional genes responsible for
LGMD2G.
In conclusion, we report LGMD2G cases for the first time from
India. In this study, among the eight Indian LGMD2G patients,
we found two telethonin mutations which include a novel c.32C.
A mutation and a reported c.26_33dupAGGTGTCG duplication;
both may be responsible for the formation of a truncated protein
or nonsense mediated decay. Further investigation is needed to
find the unknown factor for the telethonin deficiency in the
remaining six cases.
Table 4. Description of genetic analysis of TCAP gene.
Patient ID Nucleotide change Protein change State
F36-1 c.-178G.T NA Homozygous
c.453A.C p.( = ) Homozygous
F50-1 *c.32C.A p.(Ser11*) Homozygous
c.-178G.T NA Heterozygous
c.453A.C p.( = ) Heterozygous
F50-8 *c.32C.A p.(Ser 11*) Homozygous
c.-178G.T NA Homozygous
c.453A.C p.( = ) Homozygous
F50-9 *c.32C.A p.(Ser 11*) Homozygous
c.-178G.T NA Homozygous
c.453A.C p.( = ) Homozygous
F79-1 c.-178G.T NA Homozygous
c.453A.C p.( = ) Homozygous
F97-1 c.26 -33 Dup p. (Arg12fs31*) Homozygous
c.-178G.T NA Homozygous
c.453A.C p.( = ) Homozygous
F111-1 c.-178G.T NA Heterozygous
c.453A.C p.( = ) Heterozygous
F111-2 c.-178G.T NA Heterozygous
c.453A.C p.( = ) Heterozygous
F149-1 c.-178G.T NA Homozygous
c.453A.C p.( = ) Homozygous
F116-1 c.-178G.T NA Homozygous
c.453A.C p.( = ) Homozygous
*Novel mutation.
doi:10.1371/journal.pone.0102763.t004
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